Metformin/ertugliflozin

Metformin/ertugliflozin is a combination drug used for the treatment of type 2 diabetes. It combines metformin, a first-line medication for the treatment of type 2 diabetes, and ertugliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor.

Mechanism of action

Metformin works by decreasing glucose production in the liver and increasing the insulin sensitivity of body tissues. Ertugliflozin works by inhibiting SGLT2, which reduces reabsorption of glucose in the kidney, leading to excretion of glucose in urine.

Medical uses

Metformin/ertugliflozin is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It is not for treating type 1 diabetes.

Side effects

Common side effects include upper respiratory tract infection, urinary tract infection, and diarrhea. Serious side effects may include lactic acidosis, urinary tract infection, and hypoglycemia.

Interactions

Metformin/ertugliflozin can interact with other drugs such as insulin or sulfonylureas, which can increase the risk of hypoglycemia. It can also interact with diuretics, which can increase the risk of dehydration and low blood pressure.

Contraindications

Metformin/ertugliflozin is contraindicated in patients with severe renal impairment, end stage renal disease, or dialysis. It is also contraindicated in patients with a history of serious hypersensitivity reaction to ertugliflozin or metformin.

See also

• List of combined chemotherapeutic regimens
• List of antidiabetic medication

Metformin/ertugliflozin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia